Furmonertinib (a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI targeted therapy drug) has clinically significant drug-drug interactions with certain medications, and concomitant use should be avoided. The key interacting drug classes mainly include strong CYP3A4 inducers/inhibitors, gastric acid regulators, and specific chemotherapeutic agents. Before initiating treatment, patients must inform their treating physician of all medications they are currently taking (including prescription drugs, dietary supplements, and traditional Chinese medicines), and any treatment regimen adjustments must be made strictly under medical supervision.
I. Drug Classes to Avoid Concomitant Use
1. Strong CYP3A4 Inducers
Mechanism of action: Accelerate the metabolic clearance of furmonertinib, resulting in reduced plasma drug concentration and compromised therapeutic efficacy.
Representative medications: Rifampicin, phenytoin, carbamazepine, St. John's Wort extract, etc.
2. Strong CYP3A4 Inhibitors
Mechanism of action: Inhibit the metabolic degradation of furmonertinib, which may increase the risk of adverse reactions (such as diarrhea, rash, and liver injury).
Representative medications: Ketoconazole, itraconazole, clarithromycin, etc.
3. Gastric Acid Regulators
Mechanism of action: Alter the intragastric pH value, thereby affecting the intestinal absorption of furmonertinib.
Management recommendations: If concomitant use of proton pump inhibitors (e.g., omeprazole) or H2 receptor antagonists (e.g., ranitidine) is clinically necessary, an administration interval of at least 2 hours is recommended.
4. Other Medications with Potential Interactions
Dosage adjustments may be required for certain chemotherapeutic agents (e.g., CYP3A4 substrate drugs) and anticoagulants (e.g., warfarin) when used in combination with furmonertinib.
II. Precautions for Medication Use
Disclose complete medication history
This includes long-term medications for chronic conditions (e.g., antihypertensives, antidiabetics) and traditional Chinese medicines (e.g., dietary supplements containing Hypericum perforatum components).
Regular monitoring
During treatment, periodic re-examinations of liver function and blood routine are required, and patients should be monitored for the occurrence of abnormal reactions (e.g., severe diarrhea, dyspnea).
Dosage adjustment
If concomitant use of interacting medications is unavoidable, the physician may adjust the dosage of furmonertinib or substitute an alternative agent based on the patient's individual condition.
III. Management of Special Situations
Emergency medical attention
If severe adverse reactions occur after concomitant medication use (e.g., persistent high fever, jaundice, hematemesis), the drug must be discontinued immediately and emergency medical care sought promptly.
Chronic disease management
For patients with comorbidities such as hypertension and diabetes, intensified monitoring of blood pressure and blood glucose is recommended to prevent disease fluctuations caused by drug-drug interactions.
Important Reminder
Furmonertinib is a prescription-only medication. All adjustments to medication regimens, including concomitant use and discontinuation, must be carried out under the guidance of a qualified physician. Self-medication, unauthorized combination therapy, or abrupt discontinuation of the drug is strictly prohibited.
